spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Veristat Joins Decentralized Trials & Research Alliance (DTRA) to Improve the Patient Experience

Veristat

Advances commitment to support patient needs across diverse populations


SOUTHBOROUGH, MA – October 13, 2022
– Veristat, announced that it has joined an alliance of over 120 life sciences and healthcare organizations whose mission is to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (DTRA) unites industry stakeholders which include healthcare companies, regulators, patient groups, clinical research and development organizations. The Alliance is dedicated to making clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

"I am pleased to welcome Veristat to DTRA,” said Amir Kalali, MD, founder of several collaborative life science communities and co-Chair of DTRA. “By advancing decentralized research, we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies.”

When compared to more traditional methods of conducting clinical trials, decentralized clinical trials (DCTs) can have a positive impact on study sites, the clinical trial process, and the patient experience. While there are many aspects of a trial that can be decentralized, Veristat’s approach to DCTs eases the burden on patients and sites through bespoke decentralized solutions including remote monitoring, patient reported outcomes, centralized sites, e-consent, and at-home nursing. In addition, Veristat has introduced its own virtual site, inclusive of patient accrual, call-center intake, centralized rating and protocol visit completion.

"Disruption across the traditional clinical trial model has served as an accelerator to taking bold, new and inclusive approaches to conducting decentralized clinical trials for advanced therapies,” stated Shaheen Limbada, Executive Vice President of Innovation and Strategy, Veristat. “Leveraging virtual trial tools and strategies designed for complex studies supports Veristat’s goal of reducing the burden on patients while delivering increased trial efficiencies to save our sponsors time and costs.”

The current and ongoing benefits to having decentralized and virtual trial components despite the world seemingly opening up from COVID lockdowns is that the use of these components in clinical trials can reduce the strain of participation and travel on patients— one of the primary barriers to patient recruitment and retention. Additionally, decentralized approaches facilitate participation by a more diverse patient population. Inclusion of representative patient populations in clinical trials by race, age and geographic location has long been an operational challenge. To support meaningful diversity, the U.S. Food and Drug Administration (FDA) recently released updated draft guidance on the representation of racial and ethnic minorities in clinical trials. The guidance recommends sponsors submit to the FDA a Race and Ethnicity Diversity Plan early in clinical development.

"Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and impacting lives,” said Craig Lipset, DTRA co-Chair. “By taking part in DTRA, Veristat is joining the many entities that are contributing to this mission. We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders we can remove remaining barriers to adoption and impact patients today.”
phone +1 508-429-7340
web www.veristat.com
email Corporate Headquarters 134 Turnpike Road, Suite 200 Southborough, MA 01772 USA
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022

Stockley Park, UK – 3 November 2022 – Gilead Sciences, Inc. and Kite, a Gilead Company, will support 30 data presentations, including seven oral presentations in large B-cell lymphoma (LBCL) and two oral presentations on investigator-sponsored studies in acute myeloid leukaemia (AML), during the 64th Annual American Society of Hematology (ASH) Annual Meeting (10-13 December).
More info >>


White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement